Adamis Pharmaceuticals Corp. (ADMP) Trading Up 3.7%
Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) was up 3.7% during trading on Friday . The stock traded as high as $3.07 and last traded at $3.07, with a volume of 190,061 shares changing hands. The stock had previously closed at $2.96.
Separately, Maxim Group lowered their price target on Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, July 21st.
The stock has a 50 day moving average price of $2.82 and a 200 day moving average price of $5.05. The company’s market capitalization is $64.12 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/16/adamis-pharmaceuticals-corp-admp-trading-up-3-7.html
A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Adamis Pharmaceuticals Corp. by 21.8% in the second quarter. Vanguard Group Inc. now owns 335,814 shares of the specialty pharmaceutical company’s stock worth $940,000 after buying an additional 60,197 shares during the period. BlackRock Fund Advisors boosted its position in shares of Adamis Pharmaceuticals Corp. by 24.7% in the second quarter. BlackRock Fund Advisors now owns 49,806 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 9,868 shares during the period. Finally, Walleye Trading LLC boosted its position in shares of Adamis Pharmaceuticals Corp. by 118.1% in the second quarter. Walleye Trading LLC now owns 275,078 shares of the specialty pharmaceutical company’s stock worth $770,000 after buying an additional 148,966 shares during the period. Hedge funds and other institutional investors own 9.70% of the company’s stock.
About Adamis Pharmaceuticals Corp.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adamis Pharmaceuticals Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.